TAmiRNA

TAmiRNA is an Austrian biotech company based in Vienna that specializes in the discovery and validation of microRNA biomarkers and other RNA-based signatures. According to its own materials, the company is dedicated to supporting researchers and clinicians in RNA biomarker discovery, validation, and development, with the stated mission of providing innovative diagnostic solutions that improve patient outcomes, focusing on precision medicine and age-associated diseases. Its work centers on cell-free RNAs — including microRNAs, messenger RNAs, and long non-coding RNAs (lncRNAs) — and on integrating RNA signatures with AI-driven analysis to create actionable diagnostic solutions for disease detection and patient stratification. The company positions itself at the intersection of biomarker research and clinical diagnostics. Its stated focus areas include liver disease, senescence, cardiovascular disease, oncology, and bone and joint disorders, with particular emphasis on osteoporosis (OP) and cardiovascular disease (CVD) as multifactorial illnesses. TAmiRNA develops diagnostic algorithms — described as "signatures" — based on the logical combination of microRNA levels and clinical parameters, aiming to decode contributing disease factors on a personalized level and use that knowledge for better diagnosis. Beyond its own R&D, TAmiRNA operates a contract research organization (CRO) services business. It offers RT-qPCR services for microRNAs, other small and large non-coding RNAs, and messenger RNA, using target-specific LNA-enhanced (locked nucleic acid) primers for high specificity and sensitivity, with the ability to quantify from 1 up to 768 microRNAs per cDNA sample. It also provides RNA sequencing services covering mRNA, lncRNA, and circular RNA analysis across cells, tissues, biofluids, and extracellular vesicles, with full bioinformatic analysis and publication-ready reports. These services are marketed as suitable for basic, translational, and pre-clinical research as well as clinical trials, and can be applied across a wide range of organisms including human, non-human primates, mice, rats, pigs, cows, horses, dogs, Chinese hamster (CHO), C. elegans, and drosophila. The company's team includes scientific and CRO leadership; for example, Romana Bischl, PhD, is identified as Head of CRO Services, bringing expertise in cancer immunotherapy, molecular biotechnology, and preclinical development, and Tiina Berg, MSc, is identified as a Scientist in CRO Services. TAmiRNA is a private company; no parent company, ownership structure, or stock listing is indicated in the available evidence. Its public identity is built around the tagline concept of "biomarkers for more stability in life" and the goal of improving and prolonging patient stability, health, and quality of life with increasing age.

TAmiRNA is a Vienna-based biotech company focused on microRNA biomarkers and RNA-based diagnostics. Public information about the company is primarily drawn from its own website and a Wikidata entry identifying it as a company in Vienna, Austria. The available evidence does not specify a founding year, founders, or detailed corporate history, so the following account is limited to what the company itself describes about its purpose, technology, and activities. From its own descriptions, TAmiRNA was established as a biotech company specialized in the discovery and validation of microRNA biomarkers. Its stated mission is to provide validated diagnostic solutions to patients with serious aging-related illnesses, aiming to improve and prolong patient stability, health, and quality of life with increasing age. The company frames its work around the concept of "biomarkers for more stability in life" and positions itself within precision medicine. The company's technological foundation is the use of blood-circulating microRNAs — described as evolutionary conserved regulators of gene expression and cell/tissue function. TAmiRNA develops diagnostic algorithms, or "signatures," based on the logical combination of microRNA levels and clinical parameters. Its research and development activities have focused on age-associated diseases, including osteoporosis (OP), cardiovascular disease (CVD), liver disease, and aging more broadly. It describes OP and CVD as multifactorial illnesses and aims to use microRNA signatures to decode contributing disease factors on a personalized level for better diagnosis. Over time, TAmiRNA has expanded its activities beyond internal R&D into contract research services. It now offers RT-qPCR services for microRNAs, other small and large non-coding RNAs, and messenger RNA, using target-specific LNA-enhanced (locked nucleic acid) forward and reverse primers. Its microRNA platform allows parallel quantification of 1 up to 768 microRNAs per cDNA sample and is sensitive enough to analyze low RNA input samples such as biofluids, cell culture supernatants, and extracellular vesicles without pre-amplification. The company also provides RNA sequencing services for mRNA, lncRNA, and circular RNA analysis in cells, tissues, biofluids, and extracellular vesicles, with full bioinformatic analysis and publication-ready reports. These services are positioned as suitable for basic, translational, and pre-clinical research as well as clinical trials, and can be applied across a wide range of organisms. The company's team includes scientific and CRO leadership. Romana Bischl, PhD, is Head of CRO Services, with a background in cancer immunotherapy, molecular biotechnology, and preclinical development, including prior work leading preclinical development projects at Hookipa Biotech. Tiina Berg, MSc, is a scientist in CRO Services. TAmiRNA is a private company; the available evidence does not indicate any parent company, ownership group, or stock exchange listing. Its public identity remains centered on RNA biomarker discovery, validation, and the development of diagnostic solutions for complex, age-associated diseases.

A precision-medicine biotech and RNA-focused contract research provider specializing in microRNA biomarkers and diagnostic signatures for age-associated and complex diseases.

• RT-qPCR services

  Reverse-transcription quantitative PCR services for microRNAs, other small and large non-coding RNAs, and messenger RNA, using target-specific LNA-enhanced primers; supports parallel quantification of 1 to 768 microRNAs per cDNA sample and analysis of low RNA input samples without pre-amplification.

• RNA sequencing services

  3'end and whole transcriptome sequencing for mRNA, lncRNA, and circular RNA analysis in cells, tissues, biofluids, and extracellular vesicles, including total RNA extraction, quality control, library preparation, sequencing, and full statistical data analysis with publication-ready reports.

• microRNA signature diagnostic algorithms

  Diagnostic algorithms based on the logical combination of microRNA levels and clinical parameters, developed for personalized diagnosis of complex age-associated diseases.

• Extracellular vesicle (EV) isolation and characterization services

  Services for isolating and characterizing extracellular vesicles and exosomes, complementing RNA analysis workflows.

1. 1TAmiRNA - the power of microRNA biomarkers for more stabilty in lifetamirna.com
2. 2about - Tamirna - stability for life TAmiRNA Team and Partnerstamirna.com
3. 3Expert RT-qPCR Services for RNA Analysis | TAmiRNAtamirna.com
4. 4RNA Sequencing Services for Coding & Non-Coding RNAs | TAmiRNAtamirna.com
5. 5TAmiRNA (Austria) - Wikidatawikidata.org